5. UC-MSCs After Trochlear Groove Reconstruction in Dogs
Impossibile aggiungere al carrello
Rimozione dalla Lista desideri non riuscita.
Non è stato possibile aggiungere il titolo alla Libreria
Non è stato possibile seguire il Podcast
Esecuzione del comando Non seguire più non riuscita
-
Letto da:
-
Di:
A proposito di questo titolo
This week on Sit. Stay. Learn., I reviewed a 2022 study by He et al. in Frontiers in Veterinary Science that tested whether umbilical cord-derived mesenchymal stem cells (UC-MSCs) could improve recovery after trochlear groove reconstruction (TGR) in dogs. Ten healthy poodles were divided into treatment and control groups, with UC-MSCs injected intra-articularly on days 0, 7, and 14. The treated dogs showed significantly lower white blood cell and neutrophil counts on days 7 and 21, indicating less inflammation, and recovered mobility about four days faster than controls. CT and histology revealed early cartilage regeneration and restored bone contour in the UC-MSC group, while controls still had cartilage gaps. Overall, UC-MSCs appeared to reduce inflammation, speed healing, and improve joint repair without adverse effects. Since these were donor (allogeneic) cells, I’d like to see future work confirm long-term safety—one reason I often favor autologous options like Ardent’s SVF therapy. If you’ve used PRP or cell therapy in a TGR case, I’d love to hear your results at adrienne@ardentanimalhealth.com or www.ardentanimalhealth.com.